TP1031

TP1031 is a cannabinoid-based pharmaceutical candidate being developed by Tetra Pharm Technologies for the treatment of chronic pain. The drug is formulated using the company's proprietary XATEA delivery technology, which is a mucoadhesive drug delivery system designed to enhance the bioavailability and therapeutic profile of cannabinoids through sublingual or buccal administration. TP1031 targets the endocannabinoid system, primarily acting as an agonist at the cannabinoid receptors CB1 and CB2. By modulating these receptors, the drug aims to alleviate pain through the regulation of neurotransmitter release and the modulation of inflammatory pathways, offering a potential alternative to traditional analgesic therapies.